Omadacycline (tosylate)

Omadacycline (PTK 0796) tosylate, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline tosylate acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline tosylate possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline tosylate can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections[1][2][3][4].

Product Specifications

CAS Number

[1075240-43-5]

Product Name Alternative

PTK 0796 (tosylate) ; Amadacycline (tosylate)

UNSPSC

12352005

Hazard Statement

H361, H362

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/omadacycline-tosylate.html

Purity

98.29

Solubility

H2O : 12.5 mg/mL (ultrasonic)

Smiles

O=C(C1=C(O)[C@@H](N(C)C)[C@@](C[C@@]2([H])C(C(C3=C(O)C(CNCC(C)(C)C)=CC(N(C)C)=C3C2)=O)=C4O)([H])[C@@]4(O)C1=O)N.OS(=O)(C5=CC=C(C)C=C5)=O

Molecular Formula

C36H48N4O10S

Molecular Weight

728.85

Precautions

H361, H362

References & Citations

[1]Durães F, et, al. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals (Basel) . 2019 Apr 21;12 (2) :63.|[2]Macone AB, et, al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58 (2) :1127-35.|[3]Zhanel GG, et, al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs. 2020 Feb;80 (3) :285-313.|[4]Markham A, et, al. Omadacycline: First Global Approval. Drugs. 2018 Dec;78 (18) :1931-1937.|[5]Tanaka SK, et al. In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline. Antimicrob Agents Chemother. 2016 Aug 22;60 (9) :5247-53.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

Tetracycline

Citation 01

Antimicrob Agents Chemother. 2024 Jul 9;68 (7) :e0063824.|Animal Feed Science and Technology. 2014 Dec;198:323-332.|Ann Lab Med. 2021 May 1;41 (3) :293-301.|Antibiotics (Basel) . 2022 Sep 23;11 (10) :1298.|Antimicrob Agents Chemother. 2019 May 24;63 (6) . pii: e00470-19.|Antimicrob Agents Chemother. 2020 Feb 21;64 (3) :e02097-19.|Antimicrob Agents Chemother. 2023 Feb 16;67 (2) :e0145922.|Antimicrob Agents Chemother. 2024 Oct 29:e0105124.|Antimicrob Agents Chemother. 2025 May 23:e0024925.|Clin Exp Pharmacol Physiol. 2023 Jul;50 (7) :604-609.|Comput Intell Neurosci. 2022 Apr 25;2022:7636983.|Cureus. 2024 Dec 1;16 (12) :e74917.|Diagn Micr Infec Dis. 2020 Nov;98 (3) :115129.|Infect Drug Resist. 2025 Oct 4:18:5239-5247.|J Antibiot (Tokyo) . 2022 Aug;75 (8) :463-471.|J Clin Microbiol. 2020 Jan 28;58 (2) :e01603-19.|J Glob Antimicrob Resist. 2025 Aug 8:44:435-441.|J Microbiol Immunol Infect. 2025 Apr;58 (2) :219-225.|Malar J. 2025 Jun 19;24 (1) :194.|Microbiol Spectr. 2023 Feb 14;11 (1) :e0323822.|Microbiol Spectr. 2023 Jun 15;11 (3) :e0071823.|Nat Microbiol. 2023 Mar;8 (3) :410-423.|Nat Struct Mol Biol. 2023 Sep;30 (9) :1380-1392.|Open Forum Infect Dis. 2024 Oct 11;11 (11) :ofae611.|PLoS Biol. 2022 Sep 28;20 (9) :e3001808.|Research Square Preprint. 2020 Jun.|J Antimicrob Chemother. 2021 Feb 11;76 (3) :653-658.|J Antimicrob Chemother. 2021 Jul 15;76 (8) :2071-2078.|Virulence. 2022 Dec;13 (1) :77-88.